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EDITORIAL REVIEW 
Do Angiotensin-Converting Enzyme Inhibitors Prolong Life in Patients 
With Heart Failure Treated in Clinical Practice? 
MILTON PACKER,  MD, FACC 
New York, New York 
Angiotensin converting enzyme (ACE) inhibitors have emerged 
as a significant advance in the treatment of heart failure; yet only 
a minority (i.e., 30% to 40%) of eligible patients are being treated 
with these drugs, and even among treated patients, the doses used 
in clinical practice are substantially lower than those used in the 
clinical trials that established the efficacy and safety of these 
agents. The preference for low doses is based on the belief that low 
and high doses exert similar benefits but that high doses produce 
more side effects. Yet, most studies indicate that large doses of 
ACE inhibitors produce greater hemodynamic and clinical effects 
than small doses, with no additional toxicity. However, it is 
uncertain whether the survival effects of these drugs are also 
related to dose. To address this question, a large multinational, 
double.blind clinical trial (Assessment of Treatment With Lisin- 
opril and Survival [ATLAS]) was launched to compare the effects 
of low and high doses of the ACE inhibitor lisinopril on the 
survival of patients with heart failure. If the study demonstrates 
that large doses are needed to produce optimal effects on mortal- 
ity, then the low dose strategies that are now widely used in 
clinical practice may be inadvertently nullifying the enormous 
potential benefits that ACE inhibitors might otherwise have on 
public health. 
(J Am Coil Cardiol 1996;28:1323-7) 
The most important advance in the management of chronic 
heart failure during the past decade has been the development 
of agents that inhibit the angiotensin-converting enzyme 
(ACE). This class of drugs has produced hemodynamic, symp- 
tomatic and prognostic benefits in patients with left ventricular 
dysfunction beyond that which can be achieved with the use of 
conventional drugs, Numerous trials have demonstrated that 
ACE inhibition can relieve the symptoms and enhance the 
exercise capacity of patients with heart failure while producing 
few adverse reactions (1-4). In addition, in large-scale studies, 
ACE inhibitors have reduced morbidity and mortality, regard- 
less of the severity of symptoms, even in patients with an acute 
myocardial injury but without symptoms of heart failure (5- 
11). These observations, taken together, provide a compelling 
argument that ACE inhibitors hould be given to all patients 
with left ventricular systolic dysfunction, with or without 
symptoms of heart failure, as long as the drugs are well 
tolerated. If this recommendation were followed, this class of 
drugs would prevent at least 60,000 deaths and 100,000 hospi- 
tal admissions in the United States each year (6). 
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Factors  That  M ight  L imi t  the  Impact  o f  
ACE lnh ib i to rs  
Will the use of ACE inhibitors for heart failure have such 
an important impact on public health? Present surveys indicate 
that only a minority (i.e., 30% to 40%) of eligible patients in 
the United States are being treated with these drugs. Some 
physicians have yet to accept he benefits of ACE inhibitors, 
whereas others routinely avoid the use of these drugs in 
specific types of patients (e.g., those with low pretreatment 
blood pressure or mildly impaired renal function) who are 
believed to be at high risk of experiencing side effects with 
treatment. Still others readily discontinue the use of ACE 
inhibitors after a modest and asymptomatic decline in blood 
pressure or renal function. Yet, the available data indicate that 
such patients derive as much benefit from the use of ACE 
inhibitors as low risk patients. In controlled trials, patients with 
low baseline blood pressures and those who experienced 
further decreases in blood pressure responded symptomati- 
cally to ACE inhibition as well as those in whom blood 
pressure was not a concern (12). Similarly, patients with renal 
insufficiency before treatment or who had worsening renal 
function during treatment showed as great a reduction in 
mortality with ACE inhibition as those in whom renal function 
remained within normal limits before or during treatment 
(13,14). Hence, strategies that avoid the use of ACE inhibitors 
in selected groups may deprive many patients of the advan- 
tages of these drugs. 
Yet, even if physicians prescribed ACE inhibitors to all 
patients who might benefit from these drugs, such use may still 
not result in a significant decline in the risk of morbidity and 
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Figure 1. This graph (and those shown in Fig. 2 to 4) depicts 
hypothetical dose-response relations governing the use of angiotensin- 
converting enzyme inhibitors in heart failure. Here, the relation 
between dose and efficacy is assumed tobe flat (low doses are as 
effective as high doses), whereas the relation between dose and safety 
is assumed tobe curvilinear (the frequency ofside effects i dependent 
on dose). If this were true, physicians would use low doses (as shown 
in the shaded area) because such doses produce all the therapeutic 
benefits at minimal risk. 
mortality in heart failure because the doses used in clinical 
practice are far lower than those used in clinical trials. The 
doses of captopril used in controlled studies were 150 to 
300 mg daily (1,9), but the drug is usually prescribed in clinical 
practice at a daily dose of 25 to 50 rag. Similarly, the doses of 
enalapril used in large-scale trials were 20 to 40 mg daily (5-8); 
yet the drug is most commonly prescribed by physicians at a 
dose of 2.5 to 5.0 mg daily. In general, the most common dose 
of an ACE inhibitor utilized in clinical practice is similar to 
that recommended for the initiation, rather than the mainte- 
nance, of therapy. 
Reasons for Using Low Doses of ACE 
Inhibitors in Heart Failure 
Why are physicians using doses of ACE inhibitors that are 
only 10% to 25% of those used in clinical trials? Physician 
surveys indicate that this pattern of use is based on two 
principal assumptions: 
Assumption 1. Low doses are as effective as high doses but 
produce fewer side effects. Many physicians tate that their 
preference for low doses is based on the belief that low and 
high doses exert similar benefits but that high doses produce 
more side effects than low doses. This relation between dose 
and effect is illustrated in Figure 1. Figure 1 assumes that the 
dose-response r lation for the favorable effects of the ACE 
inhibitors is flat, whereas the dose-response r lation for the 
adverse effects of these drugs is steep. Because low doses 
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Figure 2. The relation between dose and efficacy is assumed tobe 
curvilinear (high doses are more ffective than low doses), whereas the 
relation between dose and safety isassumed tobe flat (low and high 
doses have a similar safety profile). Under these circumstances, 
patients would benefit only if they were treated with large doses of an 
angiotensin-converting enzyme inhibitor (shaded area). 
provide the largest difference between the drug's favorable and 
toxic effects, low doses would be preferred. 
Is there evidence to support this assumption? In early 
studies, low doses of an ACE inhibitor produced hemodynamic 
effects imilar to high doses (15,16), and in clinical practice, 
low doses produce symptomatic improvement i  many patients 
with few side effects. However, most observations indicate that 
large doses of ACE inhibitors produce greater hemodynamic 
(17,18) and clinical (19-22) effects than small doses. In one 
retrospective open-label study with captopril (19), high doses 
(>75 nag daily) produced a more favorable ffect on functional 
capacity than low doses (<75 mg daily). In a double-blind 
study with quinapril (20), exercise capacity improved more in 
patients assigned to 40 mg daily than in patients treated with 
10 mg daily. In one double-blind study with enalapril (21), 
patients allocated to 15 mg twice daily experienced fewer 
cardiovascular events than those assigned to 2.5 mg twice daily. 
In a second double-blind study with enalapril (22), patients 
assigned to high doses (20 mg twice daily) showed greater 
hemodynamic, neurohormonal and symptomatic benefits than 
those assigned to low doses (5 mg twice daily). Of note, in all 
four studies, the frequency of side effects with low doses was 
similar to that seen with high doses. Finally, in an experimental 
model of heart failure, high doses of lisinopril were superior to 
low doses of lisinopril in prolonging life (23). Taken collec- 
tively, these observations suggest that the dose-response rela- 
tions for the benefits and risks of ACE inhibitors in heart 
failure resemble those depicted in Figure 2 rather than Figure 
1; the dose-response relation for the favorable ffects is steep, 
whereas that for the adverse ffects of these drugs is flat. Yet, 
Figure 2 indicates that the use of low doses of an ACE 
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Figure 3. The relation between dose and symptoms is parallel to the 
relation between dose and survival, Note that in this graph (as well as 
that shown in Fig. 4), the y intercept for symptoms and side effects i
not zero because placebo therapy is associated with symptomatic 
improvement and side effects in some patients. Under these circum- 
stances, physicians should use low doses (shaded area), which would 
maximize the risk/benefit relation. 
inhibitor exposes patients with heart failure to all of the risks 
but provides them with few of the benefits of these drugs. 
Assumption 2. A physician can assess the effect of an ACE 
inhibitor on the survival of an individual patient by evaluating the 
drug's effect on ~'mptoms or blood pressure. Recognizing that 
Figures 1 and 2 may represent extreme points of view, many 
physicians would suggest that both the efficacy and the safely of 
ACE inhibitors are dependent on dose (i.e., high doses are 
more effective and more toxic than low doses). As a result, 
many clinicians would adopt an intermediate approach to the 
use of ACE inhibitors; specifically, they would initiate therapy 
with low doses in all patients and increase the dose only if 
patients fail to respond favorably to treatment. Accordingly, 
patients would be exposed to high doses (and their attendant 
risks) only if they had tolerated but had failed to improve with 
low doses. 
Yet, such an approach assumes that we know when we have 
reached an effective dose of an ACE inhibitor by simply asking 
the patient if his or her symptoms have improved; this would 
be true if the only reason for prescribing these drugs was to 
relieve symptoms. However, ACE inhibitors are used in the 
treatment of heart failure to reduce mortality as well as 
disability, and we do not know whether the effect of these drugs 
on survival occurs simultaneously with their effect on symp- 
toms. Many physicians believe that he dose-response relations 
for symptoms and survival are precisely parallel to each other 
(as depicted in Fig. 3), and thus, symptoms could be used as an 
end point to titrate the effect on survival. However, it is 
possible that the shapes of the dose-response curves for 
symptoms and for survival are substantially different, such that 
survival is prolonged only with the use of large doses (as 
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Figure 4. The relation between dose and survival isnot parallel to the 
relation between dose and symptoms. Under these circumstances, 
physicians should use large doses (shaded area) despite their increased 
side effects because only large doses produce favorable effects on 
survival. 
depicted in Fig. 4)--doses far greater than those needed to 
produce an optimal effect on symptoms. 
Why should the dose-response r lation for symptoms be 
different than that for survival? There are two possibilities: 1) 
The mechanisms by which ACE inhibitors affect symptoms and 
survival may be different. Symptoms may be primarily influ- 
enced by a drug's hemodynamic effects (which are apparent at 
low doses), whereas urvival may be principally mediated by a 
drug's effects on neurohormonal systems (which are most 
markedly affected at large doses) (13,19,21-24). 2) Symptoms 
are highly subjective and can be influenced by factors that have 
little to do with the pharmacologic effects of the drug, whereas 
survival is not subject o interpretative biases. For example, in 
controlled trials, 25% to 35% of patients assigned to placebo 
therapy (i.e., 0 mg of an ACE inhibitor) show a significant 
reduction in the symptoms of heart failure (25); yet, placebo 
therapy does not provide adequate effects on survival. 
Alternatively, instead of using symptoms, ome physicians 
would use a physiologic measure (e.g., blood pressure) as an 
end point for the titration of therapy, that is, they would 
initiate treatment with low doses in all patients and increase 
the dose until blood pressure (or some other variable) changes 
by a predetermined value. Such an approach assumes (without 
supporting evidence) that there is a relation between the 
hypotensive actions of the drug and its effects on mortality. 
Furthermore, because blood pressure-based titration was not 
used in any clinical trial, it is not clear that such an approach 
would achieve the same survival benefits as the use of fixed 
doses. Why, then, would physicians ubstitute a physiologic 
measure (blood pressure) for a definitive clinical end point 
(mortality)? Such a substitution primarily occurs because 
physicians cannot measure the effect of a drug on mortality in 
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an individual patient, but they can measure the drug's effect on 
blood pressure. To many physicians, the ability to measure any 
effect is more appealing than the blind acceptance of the 
empiric results of a clinical trial. They would say, "By measur- 
ing blood pressure, I know that the drug is doing something. 
How does a physician using fixed high doses know that the 
drug is prolonging life in the specific patient he is treating?" 
Although such a response ignores the fundamental fact that 
survival benefits are seen in populations, not in individuals, this 
point of view is held by many clinicians. 
What Dose of an ACE Inhibitor Should 
Physicians Use? 
Thus, even after many ears of development, there remains 
an important unresolved issue concerning the use of ACE 
inhibitors in patients with heart failure. We know a great deal 
about whether patients hould receive ACE inhibitors, but we 
know little about how patients hould receive them. What is 
the most appropriate dosing regimen? Are the low doses used 
in clinical practice as effective as the high doses used in clinical 
trials? 
To address these questions, a large multinational, double- 
blind, randomized controlled clinical trial was launched to 
evaluate the efficacy and safety of two different dosing regi- 
mens of an ACE inhibitor (lisinopril) in patients with heart 
failure. The trial is known by the acronym ATLAS (Assess- 
ment of Treatment With Lisinopril and Survival). The objec- 
tive of the study is to compare the effects of two doses of 
lisinopril--low doses (2.5 to 5.0 mg once daily) and high doses 
(32.5 to 35.0 mg once daily)--on the morbidity and mortality 
of patients with heart failure. Begun in 1993, the study has 
enrolled >3,000 patients with New York Heart Association 
functional class II or IV heart failure and a left ventricular 
ejection fraction -<30% at 288 sites in 18 countries; all patients 
will be followed up for 3 to 4.5 years. The primary end point in 
the study is all-cause mortality, and the study is intended to 
have a 90% power to detect a 15% difference between the two 
treatment groups at the end of the follow-up period. The study 
will also compare the effect of high and low doses of lisinopril 
on nonfatal end points (e.g., development of progressive heart 
failure) as well as on measures of safety. The results of the 
study will be available in late 1997. 
What should physicians do until the results of the ATLAS 
study are available? Most studies suggest hat physicians 
should prescribe the doses of ACE inhibitors used in clinical 
trials; to do otherwise is to assume--in the absence of support- 
ing data--that low doses are prognostically equivalent to high 
doses. Nevertheless, it seems likely that most physicians will 
continue to use doses that are lower than those that have been 
utilized in controlled clinical trials on the basis of the belief 
that such doses are sufficient to prolong life. Yet, the margin 
for error for selecting a dose to relieve symptoms i not the 
same as the margin of error for selecting adose to extend life. 
When treating symptoms, there is room for error because if the 
patient remains ymptomatic despite the use of low doses, the 
patient returns to the physician who now has the opportunity 
to increase the dose until symptoms are relieved. However, 
such a margin for error does not exist when ACE inhibitors are 
used to reduce mortality because physicians cannot increase a 
subtherapeutic dose of a drug into the therapeutic range in a 
patient who has died. If low doses do not prolong life, then the 
dosing strategies that are now used widely in clinical practice 
would effectively nullify the enormous potential benefits that 
ACE inhibitors would otherwise have on public health. Until 
the results of the ATLAS trial are available, is this a risk that 
physicians hould be willing to take? 
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